Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression

Immunotherapy is an effective treatment in advanced non‐small cell lung cancer (NSCLC) patients with high PDL‐1 expression. Here, we report three such patients with durable response despite limited doses immunotherapy.[Image: see text]

Detalles Bibliográficos
Autores principales: Wong, Pui Yee, How, Soon Hin, Hassan, Radhiana, Abdul Azih, Muhammad Naimmuddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
REGULAR ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711218/
https://www.ncbi.nlm.nih.gov/pubmed/34964016
http://dx.doi.org/10.1002/agm2.12179
_version_ 1784623327108661248
author Wong, Pui Yee
How, Soon Hin
Hassan, Radhiana
Abdul Azih, Muhammad Naimmuddin
author_facet Wong, Pui Yee
How, Soon Hin
Hassan, Radhiana
Abdul Azih, Muhammad Naimmuddin
author_sort Wong, Pui Yee
collection PubMed
description Immunotherapy is an effective treatment in advanced non‐small cell lung cancer (NSCLC) patients with high PDL‐1 expression. Here, we report three such patients with durable response despite limited doses immunotherapy.[Image: see text]
format Online
Article
Text
id pubmed-8711218
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87112182021-12-27 Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression Wong, Pui Yee How, Soon Hin Hassan, Radhiana Abdul Azih, Muhammad Naimmuddin Aging Med (Milton) REGULAR ARTICLES Immunotherapy is an effective treatment in advanced non‐small cell lung cancer (NSCLC) patients with high PDL‐1 expression. Here, we report three such patients with durable response despite limited doses immunotherapy.[Image: see text] John Wiley and Sons Inc. 2021-10-24 /pmc/articles/PMC8711218/ /pubmed/34964016 http://dx.doi.org/10.1002/agm2.12179 Text en © 2021 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle REGULAR ARTICLES
Wong, Pui Yee
How, Soon Hin
Hassan, Radhiana
Abdul Azih, Muhammad Naimmuddin
Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression
title Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression
title_full Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression
title_fullStr Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression
title_full_unstemmed Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression
title_short Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression
title_sort limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ecog of 2 and high pdl‐1 expression
topic REGULAR ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711218/
https://www.ncbi.nlm.nih.gov/pubmed/34964016
http://dx.doi.org/10.1002/agm2.12179
work_keys_str_mv AT wongpuiyee limiteddosesofimmunotherapyuseinadvancednonsmallcelllungcancerelderlypatientswithecogof2andhighpdl1expression
AT howsoonhin limiteddosesofimmunotherapyuseinadvancednonsmallcelllungcancerelderlypatientswithecogof2andhighpdl1expression
AT hassanradhiana limiteddosesofimmunotherapyuseinadvancednonsmallcelllungcancerelderlypatientswithecogof2andhighpdl1expression
AT abdulazihmuhammadnaimmuddin limiteddosesofimmunotherapyuseinadvancednonsmallcelllungcancerelderlypatientswithecogof2andhighpdl1expression

Ejemplares similares